Discover a recent randomised clinical trial that evaluated the efficacy of a new monoclonal antibody to treat plaque ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

Discover tapinarof cream 1%, a novel nonsteroidal aryl hydrocarbon receptor agonist, that has emerged as a promising solution ...

They can also improve the look of the affected skin. Many of the standard psoriasis treatments work for plaque psoriasis, too, as this is the most common type of psoriasis. Depending on your case ...

The US Food and Drug Administration (FDA) has approved Vtama (tapinarof) cream 1%, an aryl hydrocarbon receptor agonist, for ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

The U.S. Food and Drug Administration has approved Organon's Vtama (tapinarof) 1% cream for an additional indication -- the ...

The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

The following is a summary of “Time to Loss of Disease Control Following Guselkumab Withdrawal in Relation to Initial Speed ...

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025On track to initiate a proof-of-concept study in ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...